OR WAIT null SECS
December 10, 2021
Guide addresses challenges of applying GMPs to autologous cell therapy manufacturing.
December 09, 2021
Lonza has signed a five-year services agreement to provide for the development and manufacturing of biologics and small molecules for portfolio companies owned by Bioqube Ventures.
Leucid Bio will collaborate with Lonza to use Lonza’s Cocoon Platform for clinical and commercial manufacturing of CAR T cells for Leucid’s lead candidate.
Sanofi’s acquisition of Origimm Biotechnology will add to its pipeline of vaccine candidates for treating acne.
A new Cytiva FlexFactory platform will be installed at Taiyo Pharma Tech’s site in Osaka, Japan.
Pfizer found that two-dose recipients exhibited a more than 25-fold reduction in neutralization titers against Omicron relative to wild-type.
Doer Biologics will use Lonza’s XS technology in the production of its proprietary platform technology.
Fujifilm’s new cell culture media manufacturing facility in the Netherlands has officially opened.
The additions to Crown Bioscience’s UK facility will increase and expand the company’s current in-vivo offering.
December 08, 2021
Roche’s Actemra/RoActemra (tocilizumab) is now approved in the EU for the treatment of adults with severe COVID-19 symptoms.